| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3880 |
| Trial ID | NCT06417398 |
| Disease | Systemic Lupus Erythematosus | Idiopathic Inflammatory Myopathy | Systemic Sclerosis | Sjogren's Syndrome | Rheumatoid Arthritis | Immune Thrombocytopenia | Primary Biliary Cholangitis |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 CAR-T cells |
| Phase | Early_Phase1 |
| Recruitment status | Not Recruiting |
| Title | Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases |
| Year | 2024 |
| Country | China |
| Company sponsor | PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
| Other ID(s) | PG-005 |
| Cohort 1 | |||||||||
|
|||||||||